Therapy of chronic pain in cancer patients: Tafalgin use experience. Case report

Cover Page

Cite item

Full Text

Abstract

Background. Chronic pain is the most common and severe condition associated with cancer, causing peripheral and central nervous system disorders Inadequate pain control can be destructive and negatively affect patients' quality of life and daily activity. Therefore, developing new drugs for complete pain control during antitumor therapy and palliative care is an urgent problem in modern oncology. One of these directions is the search for selective molecules that interact with μ1-opioid receptors without many side effects of opioids.

Aim. To evaluate the effectiveness of a new selective μ1-opioid analgesic, Tafalgin, in treating chronic pain in a patient with pancreatic cancer.

Materials and methods. Tafalgin was used to control chronic pain in a 60-year-old patient with stage IV pancreatic cancer, pT2 N0M1, with liver metastases, state after 10 cycles of polychemotherapy, and distal subtotal resection of the pancreas with splenectomy, progression in October 2022, liver metastases; state after 4 cycles of polychemotherapy, severe chronic pain.

Results. The initial pain severity was evaluated using a visual analog scale: 7 points at rest and 9 points on exertion. The patient developed pain during FOLFIRINOX polychemotherapy, for which he received tramadol at a daily dose of 400 mg in combination with paracetamol, with an effect for 1.5 months. The pain severity increased with breakthrough pain. The patient was prescribed long-acting morphine at 60 mg/day, with good effect. However, the patient experienced nausea and vomiting. The morphine dose was reduced to 20 mg, thus resolving side effects and decreasing the effectiveness. Tafalgin was administered at a dose of 4 mg TID. The pain severity decreased to 1–1.2 points. No adverse events were reported. The patient has been receiving the drug for 52 days. His sleep and appetite have improved, physical activity has increased, and no weight loss has been reported.

Conclusion. When switching a patient to Tafalgin, continuous adequate pain control is maintained, not inferior to morphine. Tafalgin is associated with a favorable safety profile.

About the authors

Nikolai A. Ognerubov

Derzhavin Tambov State University

Author for correspondence.
Email: ognerubov_n.a@mail.ru
ORCID iD: 0000-0003-4045-1247

D. Sci. (Med.), Cand. Sci. (Law), Prof., Derzhavin Tambov State University

Russian Federation, Tambov

References

  1. Global Burden of Disease Study 2013 Collaborators. Global, regional, and national incidence, prevalence, and years lived with disability for 301 acute and chronic diseases and injuries in 188 countries, 1990–2013: a systematic analysis for the Global Burden of Disease Study 2013. Lancet. 2015;386(9995):743-800. doi: 10.1016/S0140-6736(15)60692-4
  2. Ferlay JEM, Lam F, Colombet M, et al. Global Cancer Observatory: Cancer Today. International Agency for Research on Cancer, Lyon. Available at: https://gco.iarc.fr/today. Accessed: 15.02.2023.
  3. Злокачественные новообразования в России в 2016 году (заболеваемость и смертность). Под ред. А.Д. Каприна, В.В. Старинского, Г.В. Петровой. М.: МНИОИ им. П.А. Герцена – филиал ФГБУ «НМИЦ Радиологии» Минздрава России, 2018 [Zlokachestvennye novoobrazovaniya v Rossii v 2016 godu (zabolevaemost i smertnost). Pod red. AD Kaprina, VV Starinskogo, GV Petrovoi. Moscow: MNIOI im. PA Gercena – filial FGBU «NMICRadiologii» Minzdrava Rossii, 2018 (in Russian)].
  4. Snijders RAH, Brom L, Theunissen M, Van den Beuken MHJ. Update on Prevalence of Pain in Patients with Cancer 2022: A Systematic Literature Review and Meta-Analysis. Cancers. 2023;15:591. doi: 10.3390/cancers15030591
  5. Breivik H, Collett B, Ventafridda V, et al. Survey of chronic pain in Europe: prevalence, impact on daily life, and treatment. Eur J Pain. 2006;10(4):287-333. doi: 10.1016/j.ejpain.2005.06.009
  6. Поддубная И.В., Яхно Н.Н., Мартынов А.И., и др. Диагностика и рациональная терапия хронической боли у онкологических пациентов. Междисциплинарный консенсус экспертов. Современная Онкология. 2018;20(2):5-17 [Poddubnaya IV, Yakhno NN, Martynov AI, et al. Diagnosis and rational therapy of chronic pain in cancer patients. Multidisciplinary consensus of expert. Journal of Modern Oncology. 2018;20(2):5-17 (in Russian)]. doi: 10.26442/1815-1434_2018.2.5-17
  7. Болевые синдромы в неврологической практике. Под ред. А.М. Вейна. М.: МЕДпресс-информ, 2001 [Bolevye sindromy v nevrologicheskoj praktike. Pod red. AM Vejna. Moscow: MEDpress-inform, 2001 (in Russian)].
  8. Evenepoel M, Haenen V, De Baerdemaecker T, et al. Pain Prevalence During Cancer Treatment: A Systematic Review and Meta-Analysis. J Pain Symptom Manage. 2022;63(3):e317-35. doi: 10.1016/j.jpainsymman.2021.09.011
  9. Hansson PT, Fields HL, Hill RG, et al. Neuropathic Pain: Pathophysiology and Treatment, Progress in Pain Research and Management Series. Seattle, WA: IASP Press, 2001.
  10. World Health Organization. Cancer pain relief. 2nd ed. Geneva, WHO. 1996.
  11. Абузарова Г.Р., Сарманаева Р.Р., Алексеева Г.С., Бражникова Ю.В. Клинический случай применения нового селективного μ1-опиоидного анальгетика Тафалгин при лечении хронической боли онкологического генеза. Современная Онкология. 2022;24(3):314-8 [Abuzarova GR, Sarmanayeva RR, Alekseeva GS, Brazhnicova YV. A clinical case of the use of a new selective μ1-opioid analgesic Tafalgin in the treatment of chronic cancer pain. Journal of Modern Oncology. 2022;24(3):314-8 (in Russian)]. doi: 10.26442/18151434.2022.3.201913
  12. Wiffen PJ, Wee B, Derry S, et al. Opioids for cancer pain – an overview of Cochrane reviews. Cochrane Database Syst Rev. 2017;7(7):CD012592. doi: 10.1002/14651858.CD012592.pub2
  13. Stein C, Schäfer M, Machelska H. Attacking pain at its source: new perspectives on opioids. Nat Med. 2003;9(8):1003-8. doi: 10.1038/nm908
  14. Колесников Ю.А., Беспалов А.Ю., Драволина О.А., Звартау Э.Э. Фармакология мю-опиоидов: пути развития. СПб: ФГБОУ ВО ПСПбГМУ им. акад. И.П. Павлова, 2021 [Kolesnikov YuA, Bespalov AYu, Dravolina OA, Zvartau EE. Farmakologiya myu-opioidov: puti razvitiya. Saint Petersburg: FGBOU VO PSPbGMU im. akad. IP Pavlova, 2021 (in Russian)].
  15. Косоруков В.С., Абузарова Г.Р., Захарочкина Е.Р., и др. Тафалгин – отечественный инновационный тетрапептидный препарат для подкожного введения: обзор результатов клинических исследований I и II фаз. Опухоли головы и шеи. 2022;12(2):89-107 [Kosorukov VS, Abuzarova GR, Zakharochkina ER, et al. Tafalgin is a Russian innovative tetrapeptide pharmaceutical for subcutaneous injection: review of the results of phase I and II clinical trials. Opukholi golovy i shei = Head and Neck Tumors. 2022;12(2):89-107 (in Russian)]. doi: 10.17650/2222-1468-2022-12-2-89-107
  16. Абузарова Г.Р., Косоруков В.С., Гамзелева О.Ю., и др. Эффективность и безопасность препарата Тафалгин у пациентов с онкологической болью. Результаты открытого сравнительного многоцентрового рандомизированного клинического исследования. Онкология. Журнал им. П.А. Герцена. 2022;11(5):38-48 [Abuzarova GR, Kosorukov VS, Gamzeleva OYu, et al. The efficacy and safety of Tafalgin in patients with cancer pain. Results of an open-label comparative multicenter randomized clinical trial. P.A. Herzen Journal of Oncology. 2022;11(5):38-48 (in Russian)]. doi: 10.17116/onkolog20221105138
  17. Raja SN, Carr DB, Cohen M, et al. The revised International Association for the Study of Pain definition of pain: concepts, challenges, and compromises. Pain. 2020;161(9):1976-82. doi: 10.1097/j.pain.0000000000001939
  18. Международная классификация болезней 11 пересмотра. Режим доступа: https://icd.who.int/ct11/icd11_mms/ru/release. Ссылка активна на 20.02.2023 [MKB 11. Mezhdunarodnaya klassifikaciya boleznej 11 peresmotra. Available at: https://icd.who.int/ct11/icd11_mms/ru/release. Accessed: 20.02.2023 (in Russian)].
  19. Brooks JV, Poague C, Formagini T, et al. Palliative Care’s Role Managing Cancer Pain During the Opioid Crisis: A Qualitative Study of Patients, Caregivers, and Clinicians. J Pain Symptom Manage. 2020;60(6):1127-35.e2. doi: 10.1016/j.jpainsymman.2020.06.039
  20. Van Den Beuken-Van Everdingen MHJ, Hochstenbach LMJ, Joosten EAJ, et al. Update on Prevalence of Pain in Patients with Cancer: Systematic Review and Meta-Analysis. J Pain Symptom Manage. 2016;51(6):1070-90.e9. doi: 10.1016/j.jpainsymman.2015.12.340
  21. Saifan AR, Bashayreh IH, Al-Ghabeesh SH, Batiha AM, et al. Exploring factors among healthcare professionals that inhibit effective pain management in cancer patients. Cent Eur J Nurs Midw. 2019;10(1):967-76. doi: 10.15452/CEJNM.2019.10.0003
  22. Gutgsell T, Walsh D, Zhukovsky DS, et al. A prospective study of the pathophysiology and clinical characteristics of pain in a palliative medicine population. Am J Hosp Palliat Care. 2003;20(2):140-8. doi: 10.1177/104990910302000213
  23. Twycross RG, Fairfield S. Pain in far-advanced cancer. Pain. 1982;14(3):303-10. doi: 10.1016/0304-3959(82)90137-3
  24. Ventafridda V, Tamburini M, Caraceni A, et al. A validation study of the WHO method for cancer pain relief. Cancer. 1987;59(4):850-6. doi: 10.1002/1097-0142(19870215)59:4<850::aid-cncr2820590432>3.0.co;2-1
  25. Grond S, Zech D, Schug SA, et al. Validation of World Health Organization guidelines for cancer pain relief during the last days and hours of life. J Pain Symptom Manage. 1991;6(7):411-22. doi: 10.1016/0885-3924(91)90039-7
  26. Walker VA, Hoskin PJ, Hanks GW, White ID. Evaluation of WHO analgesic guidelines for cancer pain in a hospital-based palliative care unit. J Pain Symptom Manage. 1988;3(3):145-9. doi: 10.1016/0885-3924(88)90160-1
  27. Shaheen PE, Legrand SB, Walsh D, et al. Errors in Opioid Prescribing: A Prospective Survey in Cancer Pain. J Pain Symptom Manage. 2010;39(4):702-11. doi: 10.1016/j.jpainsymman.2009.09.009
  28. Иванова Е.А., Воронина Т.А., Коробов Н.В., Косоруков В.С. Изучение длительности и дозозависимости анальгетического действия тетрапептида H-TYR-D-ARG-PHE-GLY-NH2 (Тафалгин) – в сравнении с морфина гидрохлоридом. Химико-фармацевтический журнал. 2022;56(9):8-12 [Ivanova EA, Voronina TA, Korobov NV, Kosorukov VS. Study of the duration and dose-response relationship of the analgesic action of the tetrapeptide H-TYR-D-ARG-PHE-GLY-NH2 (Taphalgin), a synthetic derivative of dermorphine, in comparison with morphine hydrochloride. Himiko-farmacevticheskij zhurnal. 2022;56(9):8-12 (in Russian)].

Copyright (c) 2023 Consilium Medicum

Creative Commons License
This work is licensed under a Creative Commons Attribution-NonCommercial-ShareAlike 4.0 International License.
 


This website uses cookies

You consent to our cookies if you continue to use our website.

About Cookies